Last reviewed · How we verify
ASLAN004
At a glance
| Generic name | ASLAN004 |
|---|---|
| Sponsor | ASLAN Pharmaceuticals |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Phase 2b Study of ASLAN004 in Adults With Moderate-to-Severe Atopic Dermatitis (PHASE2)
- Study of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated With Dupilumab (PHASE2)
- A Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneously Delivered ASLAN004 in Adults With Moderate-Severe Atopic Dermatitis (PHASE1)
- Study of ASLAN004 in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ASLAN004 CI brief — competitive landscape report
- ASLAN004 updates RSS · CI watch RSS
- ASLAN Pharmaceuticals portfolio CI